- Home
- INV vs CLLS Comparison
INV vs CLLS Comparison
Compare INV & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INV
- CLLS
- Stock Information
- Founded
- INV 2015
- CLLS 1999
- Country
- INV United States
- CLLS France
- Employees
- INV N/A
- CLLS N/A
- Industry
- INV
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- INV
- CLLS Health Care
- Exchange
- INV NYSE
- CLLS Nasdaq
- Market Cap
- INV 173.3M
- CLLS 144.4M
- IPO Year
- INV N/A
- CLLS 2007
- Fundamental
- Price
- INV $4.86
- CLLS $1.58
- Analyst Decision
- INV Strong Buy
- CLLS Buy
- Analyst Count
- INV 2
- CLLS 3
- Target Price
- INV $14.00
- CLLS $6.67
- AVG Volume (30 Days)
- INV 58.5K
- CLLS 47.2K
- Earning Date
- INV 05-15-2025
- CLLS 05-12-2025
- Dividend Yield
- INV N/A
- CLLS N/A
- EPS Growth
- INV N/A
- CLLS N/A
- EPS
- INV N/A
- CLLS N/A
- Revenue
- INV $1,220,000.00
- CLLS $54,748,000.00
- Revenue This Year
- INV $1,336.39
- CLLS $48.52
- Revenue Next Year
- INV $204.86
- CLLS $5.17
- P/E Ratio
- INV N/A
- CLLS N/A
- Revenue Growth
- INV 18.27
- CLLS 351.27
- 52 Week Low
- INV $3.00
- CLLS $1.10
- 52 Week High
- INV $18.75
- CLLS $3.32
- Technical
- Relative Strength Index (RSI)
- INV N/A
- CLLS 57.80
- Support Level
- INV N/A
- CLLS $1.37
- Resistance Level
- INV N/A
- CLLS $1.51
- Average True Range (ATR)
- INV 0.00
- CLLS 0.09
- MACD
- INV 0.00
- CLLS -0.01
- Stochastic Oscillator
- INV 0.00
- CLLS 75.00
About INV INNVENTURE INC
Innventure Inc creates, funds, operates, and rapidly scales companies in strategic collaboration with MNCs. It provides company creation, corporate strategy, technology optimization, operations, commercialization, and funding. Innventure analyzes the market, including proprietary data provided by MNCs, to identify where their well-protected, breakthrough technologies address market needs and have the potential to create $1B+ in new enterprise value.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.